Trinity Biotech plc TRIB
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -72.32%
- 1 year
- -77.69%
- Market cap
- 5.33M
- Revenue (ttm)
- 58.65M
- Profit margin
- -38.01%
- EPS (ttm)
- -60.00
- Shares out
- 27.52M
- Forward P/E
- -0.87
- YTD return
- -72.32%
- 1-year return
- -77.69%
- Volume
- 12.24K
- Avg volume
- 19.24K
- Open
- 6.80
- Previous close
- 6.80
- Day's range
- 6.32 – 6.80
- 52-week range
- 5.01 – 52.50
- Beta
- 1.13
2Y -44.21 (-87.20%)
Key statistics
- Enterprise value
- 347.37M
- PEG ratio
- 0.00
- Price / sales
- 0.42
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 14.00%
- Free cash flow
- -9.93M
- Total cash
- 5.32M
- Total debt
- 93.33M
- Return on equity
- 0.00%
- Short % of float
- 2.43%
- 50-day average
- 1.39
- 200-day average
- 1.90
Next earnings
Consensus EPS estimate -0.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -0.54 | -0.43 | +0.11 | +20.37% |
| Aug 14, 2024 | Jun 1, 2024 | -0.65 | -0.55 | +0.10 | +15.38% |
| May 23, 2024 | Mar 1, 2024 | 0.00 | -0.37 | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | -0.68 | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | -1.00 | — | — |
| Jul 6, 2023 | Mar 1, 2023 | 0.00 | -0.80 | — | — |
About Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Ireland
- Website
- trinitybiotech.com
News
Head-To-Head Survey: Trinity Biotech (NASDAQ:TRIB) vs. OrthoPediatrics (NASDAQ:KIDS)
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session Trinity Biotech's Liquid Cooling Unit Trinovium Enters Contract With Red Team Investments, Owner Of Modular Data Center Technology X-MDC
Trinity Biotech's Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure
Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Trinity Biotech's Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure Trinity Biotech Receives ~$7M Of Additional Investment From Funds Managed By Perceptive Advisors; Regains Compliance With Nasdaq Minimum Bid Price Requirement
Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
Your note
Sign in to keep a note on TRIB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 79.72% | 1,800,000 | 1.61M | Sep 29, 2024 |
| Hunter Associates Investment Management LLC | 15.93% | 359,810 | 322.75K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 11.08% | 250,153 | 224.39K | Sep 29, 2024 |
| Whitefort Capital Management, LP | 3.63% | 81,902 | 73.47K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.85% | 41,839 | 37.53K | Sep 29, 2024 |
| HRT Financial LP | 1.51% | 34,030 | 30.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.22% | 5,077 | 4.55K | Oct 30, 2024 |
